| Objectives:Retrospectively reviewed the clinical application of Xiaoaiping injection treatment of primary liver cancer, and investigate the model of H22 tumor immune function of mice.Methods:(1)Clinical Research:Collect 32 cases clinical data met the inclusion criteria, patients were given intravenous injection Xiaoaiping 60ml every day, Continuous application of 14 days, repeat every 3 weeks, evaluate after 2 cycles, if a stable condition, Continue to apply2 to 6 cycles in a stable condition. Observe patients'survival, cases of symptoms, the tumor response rate, changes of KPS score and AFP.(2) Experiment:Establish H22 tumor-bearing mice,and divide into 5 groups:normal control group, model group, Xiaoaiping low dose group, middle dose group Xiaoaiping, Xiaoaiping high dose group, n= 8. Drugs injected subcutaneously after 24h:Xiaoaiping low, medium and high dose groups were 7.5ml/kg,15ml/kg,30ml/kg intraperitoneal injection, once a day, for 21 days; model group with the same amount intraperitoneal injection of saline. Living conditions in mice, body weight change. Measured every 3 days the longest tumor diameter (a), the shortest path (b). Eyeballs 21 days after the mice were killed to take blood, take solid tumors, spleen, liver, kidney and other tissues, weighed and calculated inhibition rate, spleen index, spleen cells by flow cytometry in CD3+, CD4+/CD8+T cell subsets, ELISA method to measure serum IL-2 and IFN-y levels, HE staining of liver and kidney tissue pathology.Results:(1) Clinical Research:①survival:survival of patients with an average of 5.93±1.76 months, median survival time is 4, the average time to progression was 2.87±0.81 months,1 year survival rate was 12.5%.②improvement of symptoms:patients after symptoms improved after treatment, liver pain, abdominal distension, anorexia, fatigue and the rates were:75.0%,53.3%,45.5%,60.0%.③hanges in tumor lesions:After treatment in patients with no remission, stable in 21 cases, stable rate is 65.63%.④hanges of AFP:in AFP positive patients, AFP values before and after treatment by an average of paired t test between the groups there was no difference in the result of changes (P>0.05)⑤KPS score:After treatment,10 patients'KPS scores are improved,31.25%; stable in 18 cases,56.25%; stable rate is 87.5%.(2) Experiment:①eight change:body weight of mice in each group had increased, the largest increase in the normal group, model group increased at least,significant compared with this two groups (P<0.01). there are no significant differences between Xiaoaiping each group, Xiaoaiping groups and the normal group, Xiaoaiping groups and model group (P> 0.05).②effect on tumor growth:Tumor volume of Xiaoaiping group were less than model group (P<0.05), tumor weight of Xiaoaiping groups are compared with model group (P< 0.05); between Xiaoaiping groups,there are no differences in tumor weight and tumor volume (P >0.05); Xiaoaiping high, medium and low doses of tumor inhibition rates are 29.82%,32.60%, 27.64%.③impact on the spleen index:spleen index in model group decreased compared with the normal group (P<0.05); with the model group, Xiaoaiping spleen index in each group tended to increase (P>0.05).④on the CD3+, CD4+/CD8+T cell subsets distribution: compared with model group,CD3+, CD4+/CD8+of Xiaoaiping each group tend to increase, CD8+ tend to decrease, but there are no difference (P>0.05).⑤on serum IFN-γ, IL-2 effects:there are no significantly differents in IFN-y, IL-2 levels of each group (P>0.05).⑥on mice of pathological changes in liver and kidney tissues:livers and kidneys of each group have normal texture and color, no pathological changes.Conclusions:Xiaoaiping injection can significantly reduce tumor-related symptoms in patients with liver cancer,improve the quality of life,stable tumor and prolong survival. Xiaoaiping injection have a certain inhibitory effect on H22 tumor-bearing mice, it can increase immune function of tumor-bearing mice, and its anti-tumor mechanism needs further study. |
PDF Full Text Request